LPBI Newsletters

Newsletter #3 – June 2020

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Newsletter #3– June 2020

Curator: Gail S. Thornton, M.A.

Welcome to LPBI Group News, where readers can find relevant news and updates about science, business and medical innovation. This newsletter is distributed as a service for our readers.

LPBI Update

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Newsletter #3 – June 2020

Welcome to another issue of LPBI Group News, where readers can find relevant news and updates about science, business and medical innovation. This newsletter is distributed as a service for our readers.

LPBI Coronavirus Portal

Our reporting of the COVID-19 pandemic covers these categories: medical counter measures, epidemiological approach, community impact, economic impact, voices of global citizens, medical imaging and cardiovascular impact and key opinion leader perspectives, along with a breaking news corner. Please visit us at: https://pharmaceuticalintelligence.com/coronavirus-portal/

More about LPBI Group

As a global leader in health and biomedical information intelligence, LPBI Group was launched in 2012 by Dr. Aviva Lev-Ari.

Significant accomplishments were achieved in the following areas as of June 10, 2020:

Pharmaceutical (Biomed e-Series, 16 volumes in the frontiers of Life Sciences and Medicine, average volume size: 2,400 pages, 96,000 page downloads);
Media (e-Proceedings of Biotech Conferences, 70 events covered, 2013 to Present); and
electronic Scientific Publishing (Open Access Online Scientific Journal with 1,768,211 views, 5,839 scientific articles, 7,396 scientific comments by global scientists, 706 categories of research in the Journal’s ontology and 10,289 tags. Also, 113,716 page downloads in total on June 14, 2020, which is the equivalent of 49 books to have been sold).

E-Proceedings of Biotech Conferences in Real-Time Coverage

AACR Live Coverage

June 22-24, 2020 – LPBI Chief Scientific Officer Stephen J. Williams, Ph.D., reports in real-time about the virtual meeting of the American Association for Cancer Research (AACR), June 22-24. The meeting featured more than 120 sessions and 4,000 e-posters, including sessions on cancer health disparities and the impact of COVID-19 on clinical trials. Part I was held online in April and was centered only on clinical findings. Part II of the virtual meeting contained all the sessions and abstracts pertaining to basic and translational cancer research as well as clinical trial findings.

https://pharmaceuticalintelligence.com/2020/06/23/live-notes-real-time-conference-coverage-aacr-2020-aacr20-tuesday-june-23-2020-noon-245-educational-sessions/

World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

https://pharmaceuticalintelligence.com/2020/04/22/world-medical-innovation-forum-covid-19-ai-and-the-future-of-medicine-featuring-harvard-and-industry-leader-insights-mgh-bwh-virtual-event-monday-may-11-815-a-m-515-p-m-et/

COVID-19 and AI: A Virtual Conference – Human-Centered Artificial Intelligence Institute, Stanford University, 4/1/2020, 9AM PST – 3:30PM PST

https://pharmaceuticalintelligence.com/2020/04/01/covid-19-and-ai-a-virtual-conference-human-centered-artificial-intelligence-stanford-university-4-1-2020-9am-pst-330pm-pst/

Current Articles in the Digital Press

MIT Technology Review announced list of “Innovators Under 35, 2020”

In chaotic times it can be reassuring to see so many people working toward a better world. That’s true for medical professionals fighting a pandemic and for ordinary citizens fighting for social justice. And it’s true for those among us striving to employ technology to address those problems and many others.

The 35 young innovators in these pages aren’t all working to fight a pandemic, though some are: see Omar Abudayyeh and Andreas Puschnik. And they’re not all looking to remedy social injustices though some are: see Inioluwa Deborah Raji and Mohamed Dhaouafi. But even those who aren’t tackling those specific problems are seeking ways to use technology to help people.

They’re trying to solve our climate crisis, find a cure for Parkinson’s, or make drinking water available to those who are desperate for it.

https://pharmaceuticalintelligence.com/2020/06/20/mit-technology-review-announced-list-of-innovators-under-35-2020/

Philly Biotech Scene: Biobots and 3D Bioprinting (Now Called Allevi)

Biobots now known as Allevi, Inc.. Their new Biobots community has been renamed Allevi Academy.

The goal of BioBots has always been the same: Give laboratories the ability to create living things from scratch. Those things–such as pieces of tissue or bone–could then be studied with the hopes of finding cures and solving diseases.

That vision helped the company’s co-founders, Ricky Solorzano and Danny Cabrera, land on Inc.’s 30 Under 30 list in 2016. And while the original goal has remained, much has changed. In August, Cabrera, the company’s first CEO, left the Philadelphia-based startup. And in November, the company rebranded, changing its name to a more mature but far less memorable name, Allevi.

https://pharmaceuticalintelligence.com/2020/06/16/philly-biotech-scene-biobots-and-3d-bioprinting-now-called-allevi/

Elemental Coverage Health and Wellness, Including COVID-19

Interesting read from science and health journalist, Robert Roy Britt published in Elemental, a new Medium publication about health and wellness. In the article, Britt talks about the coronavirus which, he says, “seems able to infiltrate just about every inch of the human body, from the brain to the heart and lungs, into the gut, and right down to the toes, causing a dizzying array of symptoms ranging from annoying to fatal. It’s a list that doctors expect to grow even longer.”

The article continues: “Covid-19 is among the most dangerous and intractable new viral diseases seen in years, perhaps decades. It can attack almost anything in the body with devastating consequences,” says Harlan Krumholz, MD, a cardiologist at Yale New Haven Hospital. “Its ferocity is breathtaking and humbling.”

“Covid-19 is not alone among germs in generating a range of mild to serious outcomes. “Viruses are so weird,” says Yonatan Grad, MD, an assistant professor of immunology and infectious diseases at Harvard T.H. Chan School of Public Health. Grad doesn’t mean to discount the devastating effects viruses can have, but he says they can bring “all sorts of unusual manifestations.”

The herpes virus causes unsightly cold sores, for example, but can also prompt a deadly swelling of the brain. The poliovirus generates no visible symptoms in most people while about 1 in 200 ends up with parts of their bodies paralyzed. Meanwhile, Covid-19 likely has more surprises in store.

For the full story, please click either of these sites:

https://elemental.medium.com/every-covid-19-symptom-we-know-about-right-now-from-head-to-toe-bd1d47584096

https://pharmaceuticalintelligence.com/coronavirus-portal/voices-of-global-citizens-impact-of-the-coronavirus-pandemic-gail-s-thornton-m-a-richard-a-mandahl-mba-and-sudipta-saha-phd-lead-curators-e-mail-contacts-gailsthorntonyaho/voices-of-physicians-at-hospitals-caring-for-coronavirus-pandemic/

Personalized Medicine, Omics, and Health Disparities in Cancer: Can Personalized Medicine Help Reduce the Disparity Problem?

April 19, 2020 – In a Science Perspectives article by Timothy Rebbeck, health disparities, specifically cancer disparities existing in the sub-Saharan African (SSA) nations, highlighting the cancer incidence disparities which exist compared with cancer incidence in high income areas of the world [1]. The sub-Saharan African nations display a much higher incidence of prostate, breast, and cervix cancer and these cancers are predicted to double within the next twenty years, according to IARC[2]. Most importantly,

the histopathologic and demographic features of these tumors differ from those in high-income countries meaning that the differences seen in incidence may reflect a true health disparity as increases rates in these cancers are not seen in high income countries (HIC).

Most frequent male cancers in SSA include prostate, lung, liver, leukemia, non-Hodgkin’s lymphoma, and Kaposi’s sarcoma (a cancer frequently seen in HIV infected patients [3]). In SSA women, breast and cervical cancer are the most common and these display higher rates than seen in high income countries. In fact, liver cancer is seen in SSA females at twice the rate, and in SSA males almost three times the rate as in high income countries.

https://pharmaceuticalintelligence.com/2020/04/19/personalized-medicine-omics-and-health-disparities-in-cancer-can-personalized-medicine-help-reduce-the-disparity-problem/

Cholesterol-busting Gut Bacteria Affect People’s Cardiac Health

June 24, 2020 – Scientists at Broad Institute of MIT and Harvard University have discovered a group a gut bacterium that can metabolize enough cholesterol to affect metabolism. Their study in Cell Host and Microbe, found that bacteria in the intestines have lower cholesterol levels in their blood. Cholesterol is a key biological molecule that functions as a structural component of all animal cell membranes and is a precursor of steroid hormones, vitamin D, and bile acids. Two main sources of cholesterol are thought to influence concentrations of this metabolite in serum: endogenous cholesterol synthesized in the liver and exogenous cholesterol derived from dietary components of animal origin.

The study shows a roadmap of how enzymes and microbial genes can manipulate metabolism and impact human health. The concept that bacteria can metabolize cholesterol is been known for a long time, but not enough has been known of which species of bacteria was doing this. However, isolating cholesterol metabolizing bacteria and growing them in the lab proved to be difficult. https://pharmaceuticalintelligence.com/2020/06/24/cholesterol-busting-gut-bacteria-affect-peoples-cardiac-health/

Latest e-Book: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

A screenshot of a cell phone

Description automatically generated LPBI Group’s latest e-book entitled, Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS &

BioInformatics, Simulations and the Genome Ontology, offers the reader content curation with embedded videos and audio podcasts, real-time conference e-Proceedings by LPBI’s scientists and professors and archived tweets of quotes from speakers at leading biotechnology conferences.

Please click on this link on Amazon/Kindle Direct:

The book integrates in a single volume four distinct perspectives: basic science, technologies and methodologies, clinical aspects and business and legal aspects of genomics research. “The materials in this book represents the scientific frontier in Biological Sciences and Medicine related to the genomics aspects of disease onset,” said Aviva Lev-Ari, Ph.D., R.N., and founder of LPBI Group.

The book addresses:

aspects of life: the Cell, the Organ, the Human Body and Human Populations;
methodologies of genomic data analysis: Next Generation Sequencing, Gene Editing, AI, Single Cell Genomics, Evolution Biology Genomics, Simulation Modeling in Genomics, Genotypes and Phenotypes Modeling, measurement of Epigenomics effects on disease, and developments in Pharmaco-Genomics.

Additionally, artificial Intelligence in medicine is covered in Part 3 of the e-Book, which represents the frontier in this emerging field, with topics, such as the science, technologies and methodologies, clinical aspects, business and legal implications as well as the latest machine learning algorithms harnessed for medical diagnosis.

This e-book is significant because it:

contains 326 articles on topics, such as gene editing, bioinformatics and genome ontology;
incorporates 74 e-Proceedings created in real time by the Book’s authors and editors
includes four collections of Tweets representing quotes from speakers at global leading conferences on Genomics
has 13 locations of Videos and Audio Podcasts that serve to enrich the e-Reader’s experience

We welcome your comments and suggestions. Please send them to Aviva Lev-Ari at

avivalev-ari@alum.berkeley.edu.

###

Newsletter #2 – March 2020

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Newsletter #2 – March 2020

Curator: Gail S. Thornton, M.A.

Welcome to LPBI Group News, where readers can find relevant news and updates about science, business and medical innovation. This newsletter is distributed as a service for our readers.

Coronavirus Portal Launched on LPBI Group Site

The LPBI Group launched a Coronavirus Portal with eight sub-sections on its site to provide updated, real-time information about various aspects of the virus and its implications globally. Please click on this link to find out more: https://pharmaceuticalintelligence.com/coronavirus-portal/]. The Portal is also open to guest authorship.

The New England Journal of Medicine (NEJM) Coronavirus Update

Please visit this link from NEJM for relevant information related to the Coronavirus pandemic: https://www.nejm.org/coronavirus?query=RP

Following are other relevant articles and podcasts from NEJM:

PERSPECTIVE Critical Supply Shortages M.L. Ranney, V. Griffeth, and A.K. Jha

U.S. hospitals are already reporting shortages of key equipment needed to care for critically ill patients with Covid-19, including ventilators and personal protective equipment for medical staff. Adequate production and distribution of this equipment is crucial.

SOUNDING BOARD Allocating Scarce Medical Resources for Covid-19 J. Emanuel and Others

The Covid-19 pandemic has already stressed health care systems throughout the world, requiring rationing of medical equipment and care. The authors discuss the ethical values relevant to health care rationing and provide six recommendations to guide fair allocation of scarce medical resources during the pandemic. MAR 23

PERSPECTIVE: The Toughest Triage R.D. Truog, C. Mitchell, and G.Q. Daley

Of all the medical care that will have to be rationed during the Covid-19 pandemic, the most problematic will be mechanical ventilation. One strategy for avoiding debilitating distress over these decisions is to use a triage committee to buffer bedside clinicians. MAR 23

CLINICAL CONVERSATIONS

Dr. Anthony Fauci on Covid-19 Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, on talking with patients about Covid-19.

Sampling of NEJM Catalyst Articles and Podcasts

NEJM Journal Watch Summaries

Resources

The LPBI Group Launches First Podcast Featuring Stanford University Professor Marcus Feldman

Stanford University Professor Marcus Feldman was the first guest of a newly launched podcast series by The PBI Group. The series is expected to feature cutting-edge science and medical topics from scientists, clinicians and researchers behind some of the most exciting medical and scientific advances in the world.

Professor Feldman is the Burnet C. and Mildred Finley Wohlford Professor in the School of Humanities and Sciences at Stanford University and co-director of Stanford Bio-X, the Stanford Cancer Institute, the Stanford Neurosciences Institute and the Stanford Woods Institute for the Environment. He uses applied mathematics and computer modeling to simulate and analyze the process of evolution. His specific areas of research include the evolution of complex genetic systems that can undergo both natural selection and recombination, and the evolution of learning as one interface between modern methods in artificial intelligence and models of biological processes, including communication. Most notably, he helped develop the quantitative theory of cultural evolution, which he applies to issues in human behavior, and also the theory of niche construction, which has wide applications in ecology and evolutionary analysis. He also has a large research program on demographic issues related to the gender ratio in China.

He is managing editor of Theoretical Population Biology and associate editor of the journals Genetics; Human Genomics; Complexity; the Annals of Human Genetics; and the Annals of Human Biology. He is a former editor of The American Naturalist. He is a fellow of the American Academy of Arts and Sciences and of the California Academy of Science. His work received the “Paper of the Year 2003” award in all of biomedical science from The Lancet. He has written more than 600 scientific papers and 10 books on evolution, ecology, and mathematical biology.

Please visit this link: https://soundcloud.com/user-533071695/podcast-2020-02-14-gail-thornton-interviews-prof-marcus-feldman

Direct-to-Consumer Spending

Fierce Pharma recently reported on the top 10 advertising spenders for 2019. Those prescription products are: Humira, Xelianz, Dupixent, Chantix, Emgality, Ozempic, Eliquis, Keytruda, Otezla and Trulicity.

For more information on this story, please click here.

Nebula Genomics And Its Commitment to the Genome

Nebula Genomics is a San Francisco-based personal genomics service, which includes a subscription-based curation site for the latest scientific discoveries to create personalized reports. Readers can use their gene analysis tool to examine any gene of interest, their variant search tool to search an individual’s genome for specific genetic variants and their genome browser to look at sequencing data.

Visit their weekly library updates [https://blog.nebula.org/posts/weekly-updates/], as well as their blog on The Contagious Coronavirus (COVID-19) to get a primer on viruses and the role of genomics in responding to COVID-19: https://blog.nebula.org/role-of-genomics-coronavirus-covid-19/

BurnAlong Looks After Your Heart, Body and Mind

In this interview, Daniel Freedman, Co-Founder and Co-CEO of BurnAlong [https://www.burnalong.com/about-us/], a health and wellness platform used by universities, hospital and companies, describes his company that looks after an individual’s heart, body and mind. With thousands of classes and instructors across 30 categories from stress to parenting to financial wellness, BurnAlong provides users with inspiring instructors and social motivation. He brings the “best classes, programs and social experience to help people achieve their health and wellness goals. People can take classes on their own on demand or invite friends to join them live online.”

Please click on this link to see Daniel Freedman’s recent interview:

New e-Book: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

LPBI Group’s latest e-book entitled, Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology, offers the reader content curation with embedded videos and audio podcasts, real-time conference e-Proceedings by LPBI’s scientists and professors and archived tweets of quotes from speakers at leading biotechnology conferences.

Please click on this link on Amazon/Kindle Direct: https://www.amazon.com/dp/B08385KF87

The book addresses:

aspects of life: the Cell, the Organ, the Human Body and Human Populations;
methodologies of genomic data analysis: Next Generation Sequencing, Gene Editing, AI, Single Cell Genomics, Evolution Biology Genomics, Simulation Modeling in Genomics, Genotypes and Phenotypes Modeling, measurement of Epigenomics effects on disease, and developments in Pharmaco-Genomics.

This e-book is significant because it:

contains 326 articles on topics, such as gene editing, bioinformatics and genome ontology;
incorporates 74 e-Proceedings created in real time by the Book’s authors and editors
includes four collections of Tweets representing quotes from speakers at global leading conferences on Genomics
has 13 locations of Videos and Audio Podcasts that serve to enrich the e-Reader’s experience

We welcome your comments and suggestions. Please send them to Aviva Lev-Ari at

avivalev-ari@alum.berkeley.edu.

###

LPBI Update

Curator: Gail S. Thornton, MA, PhD(c)

Newsletter #1 – February 2020

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Reporter: Gail S. Thornton, M.A.

Welcome to the premier issue of LPBI Group News, where readers can find relevant news and updates about science, business and medical innovation. This newsletter is distributed as a service for our readers.

The Conference Forum is hosting Immuno-Oncology 360°, which reports on current data and developments of immuno-oncology in the science and business communities. The summit takes place on February 26-28 at the Crowne Plaza Times Square in New York.

Please visit www.io360summit.com to register and use code LPBI20 for a 20% discount.

Ahead of the conference, Immuno-Oncology 360° has created a series celebrating their women speakers in the work they are doing to fight cancer. To read the series, visit: https://theconferenceforum.org/conferences/immuno-oncology-360/io360%cb%9a-leadership-interviews/

This information is published in conjunction with the Immuno-Oncology 360° Summit.

Venture Summit Attracts Top Innovators in Silicon Valley

Leaders in Pharmaceutical Business Intelligence (LPBI) Group is one of the sponsors of Venture Summit | West, “Where Innovation Meets Capital.”

The meeting will be held on March 23-24 at the Santa Clara Convention Center, Silicon Valley.

Special offer: Register Now & Save $450 off (Use discount code “LPBI-VIP”)

For more information, please visit: https://pharmaceuticalintelligence.com/2019/12/17/venture-summit-west-where-innovation-meets-capital-march-23rd-24th-2020-santa-clara-convention-center-silicon-valley/

e-Proceedings of 15th Annual Personalized Medicine Conference at Harvard Medical School

The 15^th Annual Personalized Medicine Conference at Harvard Medical School, Boston last year [November 13-14, 2019], entitled The Paradigm Evolves, explored the science, business and policy issues facing personalized medicine. In today’s world, scientists need to understand how molecular diagnostics augmented by artificial intelligence, data analytics and digital health empowers physicians and patients in their health care decisions.

Please visit for LPBI Group coverage of the meeting, including social media activities at the conference:

https://pharmaceuticalintelligence.com/2019/07/19/15th-annual-personalized-medicine-conference-at-harvard-medical-school-the-paradigm-evolves-november-13-14-2019-%e2%80%a2-harvard-medical-school-boston-ma/

https://pharmaceuticalintelligence.com/2019/11/15/tweets-and-retweets-by-aviva1950-and-by-pharma_bi-for-15th-annual-personalized-medicine-conference-at-harvard-medical-school-the-paradigm-evolves-november-13-14-2019-%e2%80%a2/

3D Medical BioPrinting Technology Featured in Podcast

LPBI Group leaders, Aviva Lev-Ari, Ph.D., R.N., Stephen Williams, Ph.D., and Irina Robu, Ph.D., spoke with Partners in Health and Biz, a half-hour audio podcast that reaches 40,000 listeners, about the topic of 3D Medical BioPrinting Technology: A Revolution in Medicine.

Please click on this link to hear the podcast. https://www.youtube.com/watch?v=laozyrfi29c.

The topic is also the title of a recently offered e-book by the LPBI Group on 3D BioPrinting, available on Amazon/Kindle Direct [https://www.amazon.com/Medical-BioPrinting-Technologies-Patient-centered-Patient-Centered-ebook/dp/B078QVDV2W].

The 3D BioPrinting technology is being used to develop advanced medical practices that will help with previously difficult processes, such as delivering drugs via micro-robots, targeting specific cancer cells and even assisting in difficult eye operations.

The table of contents in this book includes: Chapter 1: 3D Bioprinting: Latest Innovations in a Forty year-old Technology. Chapter 2: LPBI Initiative on 3D BioPrinting, Chapter 3: Cardiovascular BioPrinting, Chapter 4: Medical and Surgical Repairs – Advances in R&D Research, Chapter 5: Organ on a Chip, Chapter 6: FDA Regulatory Technology Issues, Chapter 7: DNA Origami, Chapter 8: Aptamers and 3D Scaffold Binding, Chapter 9: Advances and Future Prospects, Chapter 10: BioInks and MEMS, Chapter 11: BioMedical MEMS, Chapter 12: 3D Solid Organ Printing and Chapter 13: Medical 3D Printing: Sources and Trade Groups – List of Secondary Material.

New e-Book: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

LPBI Group’s latest e-book entitled, Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology, offers the reader content curation with embedded videos and audio podcasts, real-time conference e-Proceedings by LPBI’s scientists and professors and archived tweets of quotes from speakers at leading biotechnology conferences.

Please click on this link on Amazon/Kindle Direct: https://www.amazon.com/dp/B08385KF87

The book addresses:

aspects of life: the Cell, the Organ, the Human Body and Human Populations;
methodologies of genomic data analysis: Next Generation Sequencing, Gene Editing, AI, Single Cell Genomics, Evolution Biology Genomics, Simulation Modeling in Genomics, Genotypes and Phenotypes Modeling, measurement of Epigenomics effects on disease, and developments in Pharmaco-Genomics.

This e-book is significant because it:

contains 326 articles on topics, such as gene editing, bioinformatics and genome ontology;
incorporates 74 e-Proceedings created in real time by the Book’s authors and editors
includes four collections of Tweets representing quotes from speakers at global leading conferences on Genomics
has 13 locations of Videos and Audio Podcasts that serve to enrich the e-Reader’s experience.

We welcome your comments and suggestions. Please send them to Aviva Lev-Ari at avivalev-ari@alum.berkeley.edu.

###

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

LPBI Group’s VAST intellectual property (IP) portfolio defined to include:

Three asset classes of TEXT: A, B, C
One asset class of Interoperable Cloud-based IT infrastructure & applications: D
One asset class of graphic images [non-text]: E
One asset class of human resources: F

LPBI Scientific Journal:

https://lnkd.in/eEw5q7N

1.7Million eReaders, 5700 scientific articles, 690 categories of research

BioMed e-Series:

https://lnkd.in/ekWGNqA

16 Volumes in Medicine

e-Proceedings:

https://lnkd.in/dc2qGAK

Corpus of 70 events covered in real time

Platform, systems and composition of methods in addition to above three universes of deep content.
Journal’s ART GALLERY – collection of biological images courtesy of Google Images and Shutterfly placed in original collages and inside articles for used ORIGINAL to EAWs on LPBI Group’s Team
The Team

LPBI Group’s PLAN for Global Projects Post Completion of BioMed e-Series and during transition to Transfer of Ownership

France – active relations with the equivalent of AMA for Journal subscription

Aviva’s Contact: JS

Spain – Dean of Madrid School of Medicine – on consideration e-Books for Medical Education

Aviva’s Contact: Dr. AF

Russia – ongoing Translation Project of all 16 e-Books to Russian

Aviva’s Contact: George

LATIN AMERICA

Aviva’s Contact: Marina Jancso

Japan – Asian largest Conference organizer in Medicine to use our e-Proceeding archive to plan Conference in 2021

Aviva’s Contact: SP

England – same as Japan

Aviva’s contact: DN

Germany – Contract with distributor to sale e-Books in Soft cover in Germany

Aviva’s Contact: Dr. BjornB

Israel – AI in Pharma algorithms are applied to our 5,700 for drug repurposing and for alternative therapeutics for the most expensive indication a Payor covers at present insurance policy

Aviva’s Contact: Ofer Markman

France – Lyon’s Biotech Hub gets access to LPBI IP for drug discovery research

Aviva’s Contact: Dr. BinahB

US – 2020 Pipeline Plans as in

https://pharmaceuticalintelligence.com/audio-podcasts/

Old Industrial Revolution Paradigm of Education Needs to End: How Scientific Curation Can Transform Education

Curator: Stephen J. Williams, PhD.

https://pharmaceuticalintelligence.com/2020/01/05/old-industrial-revolution-paradigm-of-education-needs-to-end-how-scientific-curation-can-transform-education/

Discussion on Open Access to Scientific knowledge

The REFERENCES to this article published in this Open Access Online Scientific Journal curated by Aviva and Dr. Williams

are about CURATIONS of Scientific basic research findings and clinical interpretation by EXPERTS

—>> Such curations are what LPBI Group created since 4/2012

—>> Such curations the value we bring to a potential acquirer in the LifeSciences, Medicine, pharmaceutical domain.

—>> we did it in three channels for knowledge dissemination OF OUR COLLABORATIVE formulations:

One Article Format of Curation by Experts was replicated by collaborations with other team members >5,700 TIMES
Expert Editors created electronic Table of Contents (eTOCs) for our 1st e-Book published 6/2013. We REPLICATED the process on eTOCs creation by Expert Editors SIXTEEN TIMES, 12/28/2019, last volume placed on the Medicine & Life Sciences in Kindle Store – our Genomics Volume 2 on AI in Medicine
4/2013 was first BioIT Aviva covered in real time and created the first e-Proceedings, Dr. Williams created Twitter Analytics for it, WE IMPROVED AND REPLICATED this process >70 TIMES

These three CORPUSES are seeking Transfer of Ownership and monetization in 2020.

Three Scenarios on HOW TO POSITION LPBI Group for 2020 and Beyond:

Scenario 1:

We are what we are:

1.1 Journal – 5700 scientific articles:

1400 are LHB’s

1000 are All Scientists combined

3355 are ALA’s

1.2 BioMed e-Series – average length of book: 2400 pages, Sixteen Volumes in five specialties of Medicine

– Cardiovascular – 6 volumes

– Genomics – 2 volumes

– Cancer – 2 volumes

– Immune System & Infectious Diseases – 3 volumes

– Precision Medicine – 4 volumes

1.3 Seventy eProceedings and Collections of Tweets made in Real time at 70 most prominent Biotech & Medicine Global Conferences, 2013-2020

1.4 Platform, composition of methods, workflow, templates to produce 1.1, 1.2, 1,3, above – The tools 🛠 🧰 to create curations for Journals and Books

1.5 A collection of 5,000 graphics of biological images used in 1.4

1.6 The Team

Scenario #2:

Scenario #1 plus NLP-AI derived insights

Scenario #3:

Only insights derived from the application of NLP-AI on our three CORPUSES

1.1 apply on every article,

N = 5700

1.2 apply on every eBook,

N = 16

1.3 apply on every eProceedings N = 70 and on every collection of Tweets N = 30

What is the BEST POSITIONING FOR EXIT:

Scenario #1: we are what we are

Scenario #2: Application of NLP-AI on Scenario #1

Scenario #3: Only the outcome of Scenario #2 targeted to problem solving in 12 economic segment of the economy

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com